Daiichi Sankyo Company, Limited Announces New Group Corporate Officers Effective from April 1, 2019
Daiichi Sankyo Company, Limited announced the appointment of new Group corporate officers effective from April 1, 2019. The appointments are: Katsumi Fujimoto as Member of the Board; Toshiaki Tojo as "Member of the Board Senior Executive Officer In charge of Vaccine Business and Quality & Safety Management "; Masahiko Ohtsuki as "Executive Officer Vice President of Business Development & Licensing Dept. "; Junichi Fukute as "Executive Officer Head of Supply Chain Div. "; Takeshi Hamaura as "Executive Officer Head of Pharmaceutical Technology Div. "; Shoji Hirashima as "Executive Officer Head of Global Brand Strategy Div. "; Ryoichi Watanabe as "Corporate Officer In charge of Internal Audit Dept. "; Hironobu Furuta as "Corporate Officer Head of Corporate Affairs Div. "; Koji Ogawa as "Corporate Officer Head of US Corporate Div., Daiichi Sankyo Inc. "; Seiichiro Kumakura as " Corporate Officer Vice President of Research Function, R &D Div. "; Takashi Fukuoka as " Corporate Officer Executive Vice President, R&D Affairs, Daiichi Sankyo Inc. "; Hironobu Saito as " Corporate Officer Vice President of Oncology Clinical Development Dept., Oncology Function, R &D Div. "; Wataru Takasaki as "Corporate Officer Head of R&D Div. and Vice President of Oncology Function "; Tomoji Hashiba as "Corporate Officer Vice President of Kyushu Branch, Sales & Marketing Div. "; and Miyuki Arai as "Corporate Officer Head of Quality & Safety Management Div.".